A new study reports that active beta-catenin, a specific form of the beta-catenin protein, directly drives the Wnt pathway to increase aggressiveness and invasion in osteosarcoma cells—a role distinct from conventional beta-catenin.
A new study published in Genes & Cancer reveals that active beta-catenin (ABC) directly drives transcriptional activity in the Wnt/beta-catenin pathway, enhancing aggressiveness and promoting an invasive phenotype in osteosarcoma (OS) cells. This is claimed to be the first report demonstrating this direct role, which is distinct from that of conventional beta-catenin.
Key Findings
- Lead Researchers: Co-first authors Kristin Hinton and Saima Ghafoor, with corresponding author Sujata Persad, University of Alberta, Canada.
- Publication: Volume 17 of Genes & Cancer, DOI: 10.18632/genesandcancer.244.
- Objective: To investigate the role of activated beta-catenin (ABC) in osteosarcoma progression.
The research team engineered OS cells to express either ABC or conventional beta-catenin, then compared their invasive capacity, anchorage-independent growth, and Wnt pathway transcriptional activity. The results were striking:
- ABC-expressing cells showed significantly greater invasive capacity, closely resembling highly metastatic OS lines.
- Conventional beta-catenin did not produce the same effect.
- ABC enhanced anchorage-independent growth.
- ABC increased Wnt pathway transcriptional activity, with elevated expression of matrix metalloproteinases MMP-2 and MMP-9.
"Cumulatively, these results suggest that ABC plays a role in OS progression, and this may be distinct from the role of beta-Catenin," the authors state. They further suggest that ABC may be a previously underappreciated driver of OS progression.
Implications for Treatment and Prognosis
Therapies targeting ABC formation or activity might be more specific than broader Wnt pathway inhibition.
The authors also note that elevated nuclear ABC levels may serve as a prognostic biomarker for osteosarcoma.
Background
Osteosarcoma is the most common primary bone cancer in children and adolescents. Survival rates have improved little over the past two decades, especially for metastatic cases. Understanding molecular mechanisms driving tumor progression is a priority for developing effective treatments.